Skip to main content

Table 1 Characteristics of the IgG4-RD, SSc, and control cohorts used in the study. Other treatments include mycophenolate mofetil, methotrexate, hydroxychloroquine, abatacept, cyclophosphamide, azathioprine, tocilizumab, and etanercept. RTX rituximab, lcSSc limited cutaneous, dcSSc diffuse cutaneous, ssSSc sine scleroderma, osSSc overlap scleroderma

From: Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis

  Controls IgG4-RD Systemic sclerosis
N samples 165 58 90
N per subtype na Active: 13, inactive: 45 lcSSc: 39, dcSSc: 39, ssSSc: 7, osSSc: 5
Age, years (median ± sd) 57 ± 8 61 ± 13 57 ± 12
Males/females 58/107 29/29 16/74
RTX 0 16 1
Prednisone 0 7 27
Other treatment 0 3 44
Data collection center Massachusetts General Hospital Massachusetts General Hospital University of Michigan